{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:06:15Z","timestamp":1776276375531,"version":"3.50.1"},"reference-count":5,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"DOI":"10.1136\/ejhpharm-2026-005082","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:20:35Z","timestamp":1776273635000},"page":"ejhpharm-2026-005082","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Is standard induction with mirikizumab sufficient in refractory ulcerative colitis in real-world practice?"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-3910","authenticated-orcid":false,"given":"Mar\u00eda","family":"Calvo Arbeloa","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iranzu","family":"Elcano Aguirre","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaya","family":"Arrondo Velasco","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maite","family":"Sarobe Carricas","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026041510203119000_ejhpharm-2026-005082v1.1","first-page":"1155","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis (LUCENT-1 and LUCENT-2): results from two phase 3 randomised controlled trials.doi: 10.1056\/NEJMoa2207940","volume":"401","author":"D\u2019Haens","year":"2023","journal-title":"Lancet"},{"key":"2026041510203119000_ejhpharm-2026-005082v1.2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","article-title":"New treatment options for inflammatory bowel diseases","volume":"53","author":"Verstockt","year":"2018","journal-title":"J Gastroenterol"},{"key":"2026041510203119000_ejhpharm-2026-005082v1.3","first-page":"109","article-title":"Health care costs and utilization for ulcerative colitis patients treated with biologics","volume":"24","author":"Park","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026041510203119000_ejhpharm-2026-005082v1.4","unstructured":"European Crohn\u2019s and Colitis Organisation . ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis 2022."},{"key":"2026041510203119000_ejhpharm-2026-005082v1.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2026-005082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:20:36Z","timestamp":1776273636000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2026-005082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":5,"alternative-id":["10.1136\/ejhpharm-2026-005082"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2026-005082","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}